Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Verisante Technology, Inc. Announces Exclusive Distribution Agreement with BO-Pharma BV

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Company to Attend 21st Congress of the European Academy of Dermatology in Prague, Czech Republic.

Verisante Technology, Inc. announced that the Company has entered into an exclusive agreement with BO-Pharma BV to distribute Verisante Aura™ in Belgium, the Netherlands and Luxemburg ("Benelux").

"BO-Pharma is the largest independent distributor of medical devices in the Benelux region," said Thomas Braun, President & CEO of Verisante. "With the Benelux market outselling the UK and Germany in some dermatological and skin care devices, our partnership with BO-Pharma provides us a strong foothold in this important region. BO-Pharma will not only distribute Aura™, but can also support technical training and servicing in the region."

BO-Pharma and its affiliate, Bo-Esthetics, currently distribute medical devices for skin care treatments, in addition to other devices for use in dermatological practices for a variety of other medical applications. Bo-Esthetics is a leading dermatology distributor in Benelux, distributing the world's top dermatology brands. Aura™ is a natural addition to the Company's existing product line.

"Impressive clinical study results show that Aura™, through speed and accuracy, is a device that can revolutionize the way skin cancer is diagnosed," said Dr. Henk-Peter Oonk, CEO of BO-Pharma. "The Netherlands has historically been very quick to adopt new, disruptive medical technologies, and we are confident this trend will continue with Aura™."

Last year, Aura™ received the Conformite Europeenne (CE) Mark approval, which is recognized by all the 27 Member States of the EU, including Benelux, which has a total population of over 30 million people, and approximately 1,000 dermatologists serving the region. The CE Mark allows the Company to sell Aura™ in Europe, a $78 billion medical device market.

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Breaking Through the Barriers to Lab Innovation
Here we examine the drivers behind the move for greater innovation, the challenges and current trends in laboratory informatics, and the tools that can be used to break these barriers.
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Fruit Fly Pheromone Flags Great Real Estate for Starting a Family
Finding could aid efforts to control mosquito-borne diseases like malaria by manipulating odorants
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Adult High Blood Pressure Risk Identifiable in Childhood
Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new University of Otago research suggests.
Analyzing Protein Structures in Their Native Environment
Enhanced-sensitivity NMR could reveal new clues to how proteins fold.
Supercoiled DNA is Far More Dynamic Than the “Watson-Crick” Double Helix
Researchers have imaged in unprecedented detail the three-dimensional structure of supercoiled DNA, revealing that its shape is much more dynamic than the well-known double helix.
Mini-kidneys Successfully Grown from Stem Cells
Researchers from Murdoch Childrens Research Institute have perfected a method of turning stem cells into mini-kidneys for use in drug screening, disease modelling and cell therapy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos